glp 1 receptor agonist GLP-1 agonists show promise in treating substance use disorders PDB-101: Molecule of the Month:
Description
2024:e14292
No single approach is likely to be enough
Frequency: Weekly injection (Wegovy/Ozempic) or a daily pill ( Rybelsus or the new high-dose Wegovy tablet )
They also performed a secondary analysis evaluating the incidence of stone-related events in patients without prior nephrolithiasis
Moreover, the FDA issued warnings about bad actors selling the active pharmaceutical ingredient (API) directly to consumers via the Internet, either in powder form labeled not for human consumption or in vials labeled as a research chemical, along with dosing instructions
